Clinical Research and Trials


Introducing the ZX008-2103 CDKL5 FENFLURAMINE STUDY

UCB is pleased to share information about a clinical trial opportunity for patients with CDKL5-related epilepsy. The goal of the ZX008-2103 Study is to learn more about patients with CDKL5 deficiency disorder (CDD) and determine if ZX008 will reduce the seizures in patients with disease-causing variations on the cyclin-dependent kinase-like5 gene. This study aims to enroll 100 patients aged 1-35 years in this Phase 3, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study.

Visit the CDKL5 Fenfluramine Study info at for information.


A clinical study for patients with developmental and epileptic encephalopathy

Longboard Pharmaceuticals is conducting this study. It is a Phase 1b/2a clinical study evaluating participants with DEEs.  The study’s primary objectives are to assess the safety & tolerability of LP352. Importantly, the PACIFIC study is also designed to examine key exploratory efficacy signals, including change in seizure frequency over the entire treatment period, which includes a 15-day titration period and a 60-day maintenance period.

We plan to enroll approximately 50 participants across approximately 30 study sites in North America with a variety of treatment-resistant motor seizures and seizure disorders that fall into the category of DEEs. The study is now enrolling participants who are 12-65 years old. Visit the study website.

ZTALMY® (ganaxolone) Resources & Support can be found here.

Marigold Study – CDKL5 Deficiency Disorder

*This study received FDA approval on March 18, 2022

Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder in the US. 

First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older1 ZTALMY significantly reduced major motor seizure frequency in CDD patients in the pivotal Marigold trial.

The ARCADE study adds two rare disorders, CDKL5 deficiency disorder and Duplication 15q syndrome, to TAK-935/OV935 clinical development.

*This study is no longer recruiting

We eagerly await communication from Takeda on how the CDD community might be involved in their global development for Soticlestat recently announced.

Takeda Pharmaceutical Company Limited and Ovid Therapeutics Inc. provided an overview of their TAK-935/OV935 broad clinical development programs and an extension trial for patients with developmental and epileptic encephalopathies (DEEs) who participated in a previous TAK-935/OV935 clinical study. Click here to read the full announcement.

Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome – completed

*Study results

Ataluren was ineffective in reducing seizure frequency or improving cognitive, motor, or behavioral function or quality of life in subjects with either DS or CDD due to nonsense variants.


*IFCR is passing this information along to you for information purposes; please check with your doctor first to see if your child should participate.